ym-60828 and Carotid-Artery-Thrombosis

ym-60828 has been researched along with Carotid-Artery-Thrombosis* in 4 studies

Other Studies

4 other study(ies) available for ym-60828 and Carotid-Artery-Thrombosis

ArticleYear
Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice.
    Thrombosis and haemostasis, 2004, Volume: 92, Issue:6

    Thrombosis and neointima formation limit the efficacy of coronary angioplasty. Factor Xa inhibitors and GPIIb/IIIa antagonists have shown to be effective on acute thrombosis and late neointima formation, however, their combined effects remain to be elucidated. Vascular injury was induced by FeCl(3) in the carotid artery in mice. For thrombosis studies, the test drug was orally administered 1 hour before vascular injury. For neointima studies, the test drug was orally administered 1 hour before and twice daily for 1 week after vascular injury, and then histological analysis was performed 3 weeks after vascular injury. YM466 inhibited thrombotic occlusion at 30 mg/kg with prolongation of prothrombin time (PT), and tail transection bleeding time (BT) was affected at 100 mg/kg. YM466 also inhibited neointima formation at 10 mg/kg. YM128 inhibited thrombotic occlusion and neointima formation at 10 and 30 mg/kg, respectively, with inhibition of platelet aggregation and prolongation of BT. In contrast, the combination of 10 mg/kg YM466 and 3 mg/kg YM128 inhibited thrombotic occlusion and neointima formation without affecting PT, platelet aggregation and BT. Concomitant inhibition of factor Xa and GPIIb/IIIa may provide a safer and more effective therapeutic regimen for treatment of coronary angioplasty.

    Topics: Angioplasty; Animals; Bleeding Time; Blood Coagulation; Blood Platelets; Carotid Arteries; Carotid Artery Thrombosis; Chlorides; Dose-Response Relationship, Drug; Drug Synergism; Factor Xa; Factor Xa Inhibitors; Ferric Compounds; Mice; Mice, Inbred ICR; Naphthalenes; Piperazines; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin Time; Thrombosis; Time Factors

2004
Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
    Thrombosis and haemostasis, 1998, Volume: 79, Issue:2

    We examined the antithrombotic activity of a novel synthetic inhibitor of factor Xa, YM-60828, in an electrically-induced carotid artery thrombosis model in rats. In the first experiment, the antithrombotic activity of YM-60828 after i.v. infusion was compared with those of heparin, darteparin and argatroban. Test drug was administered by i.v. infusion from 30 min before electrical stimulation to the end of the experiment. YM-60828 at 1 mg/kg/h significantly improved patency status, prolonged the time to occlusive thrombus formation and duration of patency. Heparin at 300 U/kg/h also improved these parameters, but were accompanied by a marked increase in systemic coagulation time. In the second experiment, the antithrombotic activity of YM-60828 after oral administration was compared with those of ticlopidine, cilostazol, aspirin, beraprost, ethyl icosapentate and warfarin. Test drug was orally administered to fasted rats 60 min before electrical stimulation. YM-60828 at 30 mg/kg p.o., but not ticlopidine, cilostazol, aspirin, beraprost, ethyl icosapentate or warfarin, significantly reduced the incidence of occlusion and improved carotid arterial patency. These results suggest that YM-60828 may be a promising antithrombotic agent for the treatment and prevention of arterial thrombosis which can be given by oral as well as intravenous administration.

    Topics: Administration, Oral; Animals; Anticoagulants; Antithrombin III; Arginine; Carotid Artery Thrombosis; Disease Models, Animal; Factor Xa Inhibitors; Heparin; Infusions, Intravenous; Naphthalenes; Pipecolic Acids; Piperidines; Rats; Sulfonamides

1998
Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
    Thrombosis and haemostasis, 1998, Volume: 79, Issue:4

    We examined the adjunctive effect of a novel factor Xa inhibitor, YM-60828, on vessel patency and blood loss from the operation site after successful thrombolysis with a modified tissue-type plasminogen activator (moPA) in an electrically-induced carotid artery thrombosis model in rats. Five minutes after the induction of occlusive thrombus, a test drug (YM-60828, argatroban, heparin or saline) was administered by i.v. bolus injection followed by continuous infusion. Thrombolysis was induced with moPA by i.v. bolus injection at a dose of 650,000 IU/ kg. YM-60828 at 1 mg/kg i.v. followed by 3 mg/kg/h significantly prevented reocclusion, increased the duration of patency, and improved vessel patency after successful thrombolysis without any significant increase in blood loss from the operation site. Argatroban at 1 mg/kg i.v. followed by 3 mg/kg/h and heparin at 300 U/kg i.v. followed by 150 U/kg/h also significantly improved these parameters, but were accompanied by a significant increase in blood loss. These results suggest that the factor Xa inhibitor YM-60828 may be a potent and useful adjunctive agent with a lower risk of bleeding complications than argatroban and heparin in thrombolytic therapy.

    Topics: Animals; Anticoagulants; Arginine; Blood Loss, Surgical; Carotid Arteries; Carotid Artery Thrombosis; Drug Evaluation, Preclinical; Hemorrhage; Heparin; Male; Naphthalenes; Pipecolic Acids; Piperidines; Rats; Recurrence; Reperfusion; Serine Proteinase Inhibitors; Sulfonamides; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator

1998
Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.
    European journal of pharmacology, 1998, May-29, Volume: 350, Issue:1

    The antithrombotic effects of a novel factor Xa inhibitor, YM-60828 ([N-[4-[(1-acetimidoyl-4-piperidyl)oxy]phenyl]-N-[(7-amidino-2-nap hthyl)methyl]sulfamoyl]acetic acid dihydrochloride), in three thrombosis models in guinea pigs were studied in comparison with its effect on bleeding time. The antithrombotic effects of YM-60828 were most pronounced in the venous thrombosis and the arterio-venous shunt models but YM-60828 showed 10-fold weaker effects in the carotid thrombosis model. However, YM-60828 prolonged bleeding time at a much higher dose than that required in all thrombosis models. In conclusion, YM-60828 exerted its antithrombotic effects without prolonging bleeding time in all thrombosis models and may be of clinical value not only in venous thrombosis but also in arterial thrombosis.

    Topics: Animals; Antithrombin III; Arteriovenous Shunt, Surgical; Bleeding Time; Carotid Artery Thrombosis; Carotid Artery, Internal; Disease Models, Animal; Factor Xa Inhibitors; Fibrinolytic Agents; Guinea Pigs; Male; Naphthalenes; Piperidines; Thrombophlebitis; Thrombosis

1998